We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

176 hedge funds and large institutions have $394M invested in PDL BioPharma, Inc. in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 65 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more call options, than puts

Call options by funds: $214K | Put options by funds: $204K

2% more capital invested

Capital invested by funds: $387M → $394M (+$7.39M)

6% less funds holding

Funds holding: 187 → 176 (-11)

28% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 65

33% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 27

Holders
176
Holders Change
-11
Holders Change %
-5.88%
% of All Funds
4.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
47
Reduced
65
Closed
27
Calls
$214K
Puts
$204K
Net Calls
+$10K
Net Calls Change
+$212K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$4.37M
2
Northern Trust
Northern Trust
Illinois
+$4.31M
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$3.12M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.08M
5
Invesco
Invesco
Georgia
+$2.76M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$6.39M
2
Norges Bank
Norges Bank
Norway
-$3.76M
3
Millennium Management
Millennium Management
New York
-$3.61M
4
State Street
State Street
Massachusetts
-$2.78M
5
SCP
Seizert Capital Partners
Michigan
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
26
SG Americas Securities
New York
$3.3M +$821K +300,825 +37%
Man Group
27
Man Group
United Kingdom
$3.21M +$2.99M +1,093,640 New
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$3.13M +$480K +175,876 +20%
Goldman Sachs
29
Goldman Sachs
New York
$2.87M -$1.04M -381,065 -28%
Allianz Asset Management
30
Allianz Asset Management
Germany
$2.75M -$76.9K -28,183 -3%
UBS Group
31
UBS Group
Switzerland
$2.73M +$509K +186,343 +25%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$2.69M -$848K -310,684 -25%
Robeco Institutional Asset Management
33
Robeco Institutional Asset Management
Netherlands
$2.56M – – –
DZ Bank
34
DZ Bank
Germany
$2.53M – – –
BCM
35
Bridgeway Capital Management
Texas
$2.5M – – –
BIP
36
Brandes Investment Partners
California
$2.41M -$764K -279,777 -25%
Skandinaviska Enskilda Banken (SEB)
37
Skandinaviska Enskilda Banken (SEB)
Sweden
$2.4M -$114K -41,800 -5%
Prudential Financial
38
Prudential Financial
New Jersey
$2.24M -$748K -273,900 -26%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$2.19M -$391K -143,100 -16%
Deutsche Bank
40
Deutsche Bank
Germany
$2.13M +$155K +56,685 +8%
SFM
41
Systematic Financial Management
New Jersey
$1.67M -$89.3K -32,730 -5%
MERSOM
42
Municipal Employees' Retirement System of Michigan
Michigan
$1.47M +$112K +41,120 +9%
Two Sigma Investments
43
Two Sigma Investments
New York
$1.44M -$1.06M -387,492 -44%
GCP
44
GSA Capital Partners
United Kingdom
$1.15M +$95.8K +35,095 +10%
TCIM
45
TIAA CREF Investment Management
New York
$1.11M -$238K -87,200 -19%
AA
46
ALPS Advisors
Colorado
$1.07M +$124K +45,449 +14%
Wells Fargo
47
Wells Fargo
California
$1.03M -$119K -43,575 -11%
SCM
48
Sterling Capital Management
North Carolina
$1.01M – – –
HIM
49
Hillsdale Investment Management
Ontario, Canada
$993K – – –
KBC Group
50
KBC Group
Belgium
$976K +$31.4K +11,494 +4%
1
2
3 4 5

PDLI Hedge Fund Activity: Q1 2018 in Review

176 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2018, worth a combined $394M — up 1.9% from $387M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of PDLI and 18 opened new positions — a net loss of 9 holders — while 65 trimmed existing stakes and 47 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $4.37M. The largest seller was Morgan Stanley, cutting an estimated $6.39M.

  • 176 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2018, down from 187 in Q4 2017.
  • Funds reported $394M of PDL BioPharma, Inc. stock for Q1 2018, up 1.9% quarter-over-quarter.
  • 18 funds opened new PDL BioPharma, Inc. positions in Q1 2018 and 27 closed out, a net change of -9 holders.
  • The largest PDL BioPharma, Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $4.37M added.
  • The largest PDL BioPharma, Inc. seller in Q1 2018 was Morgan Stanley, an estimated $6.39M sold.

Based on aggregated 13F filings for Q1 2018.